Comparison · NCT02246127-sae
Everolimus vs STZ - 5FU: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Everolimus vs STZ - 5FU: serious adverse events. Trial comparisons, record NCT02246127-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02246127-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.267 | 0.191 | 0.358 | wilson | |
| Risk in group 2 | 0.25 | 0.177 | 0.341 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0167 | -0.102 | 0.134 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.674 | 1.69 | log | |
| Odds ratio, group 1 over group 2 | 1.09 | 0.587 | 2.03 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Everolimus than on STZ - 5FU | 60 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Everolimus | Drug: Everolimus: 10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops. | 28 | 105 | EG000 |
| Group 2 | STZ - 5FU | STZ-5FU: 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops. | 26 | 104 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the time the patient signs IC for the study until 30 days after the intake of the last dose of treatment; up to approximately 5 years
Source ClinicalTrials.gov
Trial
- Title
- Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor
- NCT number
- NCT02246127
- Phases
- PHASE3
- Conditions
- Neuroendocrine Tumors
- Interventions
- Drug: Everolimus, STZ-5FU
- Lead sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Results first posted
- 2025-05-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02246127?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02246127-sae